ANTHERA PHARMACEUTICALS INC (OTCMKTS:ANTH) Could Improve Your Long Portfolio After Less Shorts Reported

October 2, 2018 - By Peter Erickson

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Logo

The stock of ANTHERA PHARMACEUTICALS INC (OTCMKTS:ANTH) registered a decrease of 4.89% in short interest. ANTH’s total short interest was 396,400 shares in October as published by FINRA. Its down 4.89% from 416,800 shares, reported previously. With 245,300 shares average volume, it will take short sellers 2 days to cover their ANTH’s short positions.

The stock decreased 4.73% or $0.00355 during the last trading session, reaching $0.07145. About 39,632 shares traded. Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) has declined 94.34% since October 2, 2017 and is downtrending. It has underperformed by 109.96% the S&P500.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $1.87 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>